

Patient Report

Specimen ID: 060-544-7409-0 Control ID: B0072202977

Acct #:))))

Phone: (775) 398-3635

Rte: 00

Specialty Health - LA Acct 7303 World Wy W 2nd Fl Los Angeles CA 90045

րդ են ինակագիր իրակույին ինկարարի համահերի

Patient Details

BAKER, SHAWN

DOB:)) Age(y/m/d): 51 Gender: M SSN: **Patient ID:**

Specimen Details

Date collected: 03/01/2018 0955 Local

Date received: 03/01/2018 **Date entered:** 03/01/2018

Date reported: 03/04/2018 1309 ET

Physician Details

Ordering: S HALL **Referring:** ID: 17707549

NPI: 1255767521

General Comments & Additional Information

Alternate Control Number: B0072202977

Total Volume: Not Provided

Alternate Patient ID: Not Provided

Fasting: No

Ordered Items

NMR LipoProf+Graph; TSH; Vitamin D, 25-Hydroxy; Lipoprotein (a); Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
NMR LipoProf+Graph					
LDL Particle Number					01
LDL-P	1273	High	nmol/L	<1000	01
			Low	< 1000	
			Moderate	1000 - 1299 Ligh 1300 - 1599	
			High	1600 - 2000	
			Very High	> 2000	
Lipids					01
LDL-C	141	High	mg/dL	0 - 99	
			Optimal	< 100	
			Above optima		
			Borderline High	130 - 159 160 - 189	
			Very high	> 189	
Comment:					01
LDL-C is inaccurate	if patient is	non-fas	sting.		
HDL-C	40		mg/dL	>39	01
Triglycerides	54		mg/dL	0 - 149	01
Cholesterol, Total	192		mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total)	28.0	Low	umol/L	>=30.5	01
Small LDL-P	283		nmol/L	<=527	01
LDL Size	21.3		nm	>20.5	01
	INTERPRETATIVE RTICLE CONCENTR				
	<lower cvd="" r<="" td=""><td></td><td>Higher CVD Ri</td><td>.sk></td><td></td></lower>		Higher CVD Ri	.sk>	
LDL AND HDL PARTI		le in E	Reference Pop	oulation	
HDL-P (total)			50th 25th		
Small LDL-P		.9 3 5th 5	30.5 26.7 50th 75th	<26.7 High	
	10W 23		, 5011	3	

117

527

839

<-Small (Pattern B)->

>839

LDL Size

<117

<-Large (Pattern A)->





Patient: BAKER, SHAWN DOB: 4 4 4 4 4

Patient ID: Control ID: B0072202977

Specimen ID: 4 4 4 4 4 4 4 4 4 Date collected: 03/01/2018 0955 Local

	TESTS		RES	SULT	FLAG		IINTTS	REFER	ENCE	INTERVAL	LAB
	12515	23		20.6	1 1110	20		19.0			
	ent: Small LDL-P a LDL-P is take These assays determined by US Food and D laboratory va	n into ac were deve LipoScie rug Admin	count. loped nce. T istrat	and these ation. T	neir per assays l The clir	rforma nave r nical	ance ch not bee utilit	aracte n clea	eristi ared b	.cs	01
Insu	lin Resistanc	e Score									01
	R Score INSULIN RESIS <insuli insulin="" lp-ir="" pe="" resis="" score<="" td=""><td>n Sensiti rcentile tance Sco</td><td>ve in Ref ore</td><td></td><td>in Resis e Popula 75th</td><td></td><td>></td><td><=</td><td>45</td><td></td><td>01</td></insuli>	n Sensiti rcentile tance Sco	ve in Ref ore		in Resis e Popula 75th		>	<=	45		01
	HF-IK SCOLE			15	63	>63					
	ent: LP-IR Score i The LP-IR sco associated wi used as one c LP-IR score l Drug Administ	s inaccur re is a l th insuli omponent isted abo	rate if aborat n resi of a p	pation pation participation pa	eveloped e and di lan's ci	d inde iabete linica	ex that es risk al asse	has k and s ssment	should . The	<u> </u>	01
NMR	PDF Image			•							01
TSH				3.010			uIU/ml	. o	.450	- 4.500	02
	vitamin D def Medicine and level of seru The Endocrine insufficiency 1. IOM (Insti intakes fo National A 2. Holick MF, Evaluation deficiency guideline.	iciency han Endocr m 25-OH v Society as a lev tute of M r calcium cademies Binkley , treatme	rine Soritaming went of rel bet ledicing and I Press. NC, Bient, and corine	ociety n D les on to f tween 2 ne). 2(). Wash schoff nd prev Societ	practions than further 21 and 2010. Die nington 5-Ferral vention	ce gu: 20 ng defir 29 ng, etary DC: Ti HA, of v: ical p	ideline g/mL (1 ne vita /mL (2) refere The , et al itamin	te of e as a .,2). min D ence	30.0	- 100.0	02
Lipop	rotein (a)	Note:	indica but mu to non influe	ate an ist be i-Cauca	ter than indepen evaluat asian po genet:	ndent ted wi opulat	risk f ith cau	to 75 ractor wition w	nmol/I for C when a the	CHD, applied	01



Patient Report

Patient: BAKER, SHAWN DOB: 4 4 4 4 4 **Specimen ID:** 4 4 4 4 4 4 **Patient ID:** Control ID: B0072202977 Date collected: 03/01/2018 0955 Local


01	BN	LabCorp Burlington	Dir: William F Hancock, MD
02	so	1447 York Court, Burlington, NC 27215-3361 LabCorp San Diego 13112 Evening Creek Dr So Ste 200, San Diego, CA	Dir: Jenny Galloway, MD
		92128-4108	

For inquiries, the physician may contact Branch: 800-859-6046 Lab: 800-762-4344



Medical Director: William F Hancock, MD

	Number -7409-0		Patient ID	Account Number Account Phone 04026090 (775) 398-3635		Account Fax (775) 398-3635				
	Patient Last Name BAKER		Patient First Name SHAWN	Account Address Specialty Health - LA Acct						
Age 51	Date of Birth 01/10/1967	Sex M	Fasting NO	7303 World Wy W 2nd Fl				· · ·		
	Control Number B0072202977		NPI 255767521	Los Angeles, CA 90045						
Date Collected 03/01/2018	Date Entered 03/01/2018		and Time Reported 2018 02:58 AM ET	Physician ID 8 17707549 - I		Page Number 1 of 2				






Medical Director: William F Hancock, MD

· ·	Specimen Number 060-544-7409-0		Patient ID	Account Number 04026090	Account Fax (775) 398-3635					
	Patient Last Name BAKER		atient First Name SHAWN	Account Address Specialty Health - LA Acct						
Age 51	Date of Birth 01/10/1967	Sex M	Fasting NO	7303 World Wy W 2nd Fl						
	Control Number B0072202977		NPI 255767521	Los Angeles, CA 90045		5				
Date Collected 03/01/2018	Date Entered 03/01/2018		and Time Reported 018 02:58 AM ET	Physician ID 8 17707549 - I		Page Number 2 of 2				

PARTICLE CONCENTRATION AND SIZE



* These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values has not been fully established.

Insulin Resistance Score(2)(3)		Insulin Sensitiv	е			Insulin Resistant
insulin Resistance Score(2)(3)			Percentile in Reference Population①			
	0-100	insulin sensitive	25th	50th	75th	insulin resistant
LP-IR SCORE**	36		27	45	63	
				A		

LP-IR Score is inaccurate if patient is non-fasting.

** The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score has not been cleared by the US Food and Drug Administration.

Clinician Notes

③ Mackey RH et al., Diab Care 2015; 38:628-36.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.